Management tracks

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), which is developing complement factor D ( CFD; adipsin) inhibitors for ultra-rare diseases, named Joel Barrish CSO. He was VP and head of discovery chemistry at Bristol-Myers Squibb Co. (NYSE:BMY).

Endocrinology company Chiasma Inc. (NASDAQ:CHMA) named Tara McCarthy SVP and general counsel. McCarthy was VP of commercial law at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). ...